Dermatophagoides farinae mite allergen and specific immunotherapy in Shanghai

Abstract

Studies on mite allergy had been launched by the Shanghai First Medical College since 1970's in this country. The preparations of SMU-Df from the local specimens of Dermatophagoides farinae (Df) in Shanghai have been shown the highest allergenic potency in comparison with that of the foreign ones, including the Df preparations from USFDA, VUS and ALK. Similar patterns of the protein curves were yielded by gel filtration, indicating almost similar allergenicities with both Df pure mite body and its spent culture medium. Around 80% of the allergic cases were sensitive to mite allergen and can be diagnosed by skin prick test, nasal provocation test and serum IgE level assay. Seasonal classic immunotherapy for allergic patients by Injection Dermatophagoides farinae, the first commercial allergen licensed by the Chinese government, achieved significant effect in relieving symptoms of allergic disorders in majority of cases, and long lasting effect of mite specific immunotherapy was also documented with minimal adverse reactions. Modifications of the Df crude extract and various modes of treatment have been studied. Studies on sublingual mite vaccine for mite allergic disorders developed synchronously with foreign trend since 1992. Sublingual drops were well acceptable by child cases almost without age restriction with higher efficacy. Rush schedule of mite immunotherapy led to a quick relief of allergic symptoms and long lasting curative effects. The Df allergen induced immunological regulation of human beings was established not only among the atopic patients, but also in healthy persons.